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Effect of a High and Low Dose of Caffeine  
on Antigen-Stimulated Activation of Human Natural  
Killer Cells After Prolonged Cycling
Deborah K. Fletcher and Nicolette C. Bishop
This study investigated the effect of a high and low dose of caffeine on antigen-stimulated natural killer (NK) cell (CD3–
CD56+) activation after prolonged, strenuous cycling, as assessed by the early-activation molecule CD69. In a randomized 
crossover design, 12 healthy male endurance-trained cyclists cycled for 90 min at 70% VO2peak  60 min after ingesting 
either 0 (PLA), 2 (2CAF), or 6 (6CAF) mg/kg body mass of caffeine. Whole blood was stimulated with Pediacel (5 in 
1) vaccine. A high dose of caffeine (6CAF) increased the number of CD3–CD56+ cells in the circulation immediately 
postexercise compared with PLA (p < .05). For both 2CAF and 6CAF, the geometric mean fluorescence intensity (GMFI) 
of CD69+ expression on unstimulated CD3–CD56+ cells was significantly higher than with PLA (both p < .05). When 
cells were stimulated with antigen, the GMFI of CD69 expression remained significantly higher with 2CAF than with 
PLA 1 hr postexercise (p < .05). Although not achieving statistical significance, 6CAF also followed a similar trend when 
stimulated (p = .09). There were no differences in GMFI of CD69 expression between 2CAF and 6CAF. These results 
suggest that a high (6 mg/kg) dose of caffeine was associated with the recruitment of NK cells into the circulation and 
that both a high and low (2 mg/kg) dose of caffeine increased unstimulated and antigen-stimulated NK-cell activation 1 
hr after high-intensity exercise. Furthermore, there does not appear to be a dose-dependent effect of caffeine on NK-cell 
activation 1 hr after prolonged intensive cycling.
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Caffeine is a trimethylxanthine that is legally and 
socially acceptable and as such is the most widely 
consumed behavior-influencing substance in the world 
(Graham, 2001). Many athletes consume caffeine for its 
known ergogenic effects, and its prevalence is increasing 
among the athletic population since being legitimized by 
its recent removal from the World Anti-Doping Agency’s 
list of prohibited substances (Chester & Wojek, 2008). It 
has been well documented that caffeine between the doses 
of 3 and 6 mg/kg body mass enhance athletic performance 
(Graham, 2001), but doses as low as 2 mg/kg body mass 
(~150–200 mg) have also been proven ergogenic (Cox et 
al., 2002; Jenkins, Trilk, Singhal, O’Connor, & Cureton, 
2008).
Natural killer (NK) cells are part of the innate 
immune system and comprise around 5–20% of all lym-
phocytes in peripheral blood (Andoniou, Andrews, & 
Degli-Esposti, 2006). These cells are distinct from other 
lymphocytes because they do not need prior sensitization 
or require specific antigen recognition to kill target cells. 
NK cells represent the “first line of defense” against infec-
tious agents, playing a pivotal role in defense against viral 
infection and tumor immune surveillance (Andoniou et 
al., 2006). However, these functional responses typically 
decrease after high-intensity exercise (as reviewed by 
Gleeson, 2007), and it is thought that this decrement may 
partly account for the apparent high incidence of viral 
respiratory infection experienced by some elite athletes. 
At rest (unstimulated), low levels of functionally active 
CD69 are expressed on NK cells (Borrego, Robertson, 
Ritz, Peña, & Solana, 1999). CD69 is one of the earliest 
cell-surface antigens expressed by lymphocytes after 
activation (Ziegler, Ramsdell, & Alderson, 1994) and 
once expressed is thought to play an essential role in 
subsequent cytokine production, proliferation, and cyto-
toxicity (Borrego et al., 1999; McFarlin, Flynn, Stewart, 
& Timmerman, 2004). As such CD69 expression appears 
to indicate a cell’s capability to recognize a potential 
antigenic/mitogenic threat and begin responding (Green, 
Rowbottom, & Mackinnon, 2003).
NK cells express both adenosine receptors (A1, A2A, 
and A2B) and β2-adrenoreceptors, with the density of these 
receptors increased after activation (Priebe, Platsoucas, 
& Nelson, 1990; Shephard, 2003). Increased concentra-
tions of adenosine and epinephrine have been shown to 
inhibit NK-cell function in vitro and in vivo (Kappel et 
al., 1991; Priebe et al., 1990) via activation of adenylate 
cyclase and increased intracellular cAMP (Raskovalova, 
Lokshin, Huang, Jackson, & Gorelik, 2006). Strenuous 
exercise increases the plasma concentrations of both 
adenosine and epinephrine (Hartley et al., 1972; Vizi et 
al., 2002). It follows, therefore, that altering the effects 
of adenosine and epinephrine during intensive exercise 
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could affect subsequent NK-cell responses. Given that 
caffeine is a nonselective adenosine-receptor antagonist 
and also stimulates epinephrine release from the adrenal 
medulla, ingesting caffeine before exercise could influ-
ence NK-cell responses after exercise.
Despite the widespread use of caffeine reported 
among the athletic population to enhance performance, 
little research has investigated the effect this drug may have 
on an athlete’s immune system after high-intensity exercise 
and the subsequent risk of infection. Of the handful of 
studies that have been published to date investigating the 
effect of caffeine on various immune functions after high-
intensity exercise, all have used a large (6 mg/kg) dose of 
caffeine (Bishop, Smith, Fitzgerald, Porter, & Scanlon, 
2005; Walker, Caudwell, Dixon, & Bishop, 2006). Many 
athletes do not consume large amounts of caffeine (~450 
mg) in one bolus dose; instead they tend to ingest much 
smaller amounts (~200 mg) to enhance performance 
(Chester & Wojek, 2008). A study by Kantamala, Vong-
sakul, and Satayavivad (1990) demonstrated that different 
doses of caffeine exert differential influences over NK-cell 
cytotoxic activity in rats at rest. Caffeine doses of 5–40 
μg/ml had little effect on NK-cell cytotoxicity in vitro. 
However, a 6-mg/kg dose of caffeine in vivo significantly 
decreased NK-cell function, whereas both 2- and 18-mg/
kg caffeine doses had no effect. To our knowledge no 
study to date has investigated the effect of different doses 
of caffeine on human NK-cell function after a bout of 
high-intensity exercise. Initial work from our group has 
shown that ingesting 6 mg/kg body mass caffeine 1 hr 
before 90 min of cycling at 70% VO2peak increases NK-
cell activation 1 hr postexercise compared with placebo 
(Fletcher, Bowry, Noon, & Bishop, 2008). Therefore, the 
aim of this study was to determine the effect of a high and 
low dose of caffeine on NK-cell activation after 90 min of 
cycling at 70% VO2peak, as assessed by the early-activation 
marker CD69. An initial pilot study was also undertaken 
to ascertain any effects of the different doses of caffeine 
on antigen-stimulated NK-cell activation at rest.
Methods
Participants
Twelve endurance-trained male cyclists (M ± SD; age 22 
± 2 years, body mass 71 ± 6 kg, VO2peak 61 ± 4 ml · kg–1 · 
min–1, peak power output 330 ± 25 W) volunteered to par-
ticipate in this study. All participants were fully informed 
about the rationale for the study, along with their possible 
risks and discomforts, before providing written informed 
consent. The local ethical advisory committee approved 
the study. At an initial health screening, participants did 
not report taking any medications or experiencing any 
symptoms of upper respiratory tract infection in the 4 
weeks before the study. They also completed a physi-
cal activity questionnaire and a caffeine-consumption 
questionnaire during the initial screening. Before each 
additional laboratory visit a subsequent health-screening 
questionnaire was administered. Daily caffeine intake 
among participants varied and ranged from 30 to 359 
mg/day. One participant was characterized as a high user 
(>250 mg/day), 6 as moderate users (50–250 mg/day), 
and 5 as light users (<50 mg/day).
Pilot Study
Before the preliminary testing took place, a resting pilot 
study was undertaken to determine whether there was 
any effect of caffeine at a dose of 0, 2, or 6 mg/kg body 
mass on unstimulated and antigen-stimulated lymphocyte 
activation (as assessed by the early-activation molecule 
CD69). Six healthy participants (age 25 ± 3 years, weight 
76 ± 6 kg) were randomly assigned to the placebo (PLA), 
2-mg/kg body mass caffeine (2CAF), or 6-mg/kg body 
mass caffeine (6CAF) trial and acted as their own con-
trols. Participants reported to the laboratory at 8:20 a.m. 
under the same conditions as in the exercise trial. They 
rested quietly in the laboratory for 3.5 hr, during which 
time blood samples were collected to coincide with 
time points during the main exercise trials (presupple-
ment, preexercise, postexercise, and 1 hr postexercise). 
The results from this group of participants are shown in 
Table 1. The number of CD3–CD56+ cells was higher 1 hr 
and 2.5 hr after caffeine ingestion with 6CAF than with 
PLA or 2CAF (p < .05; Table 1). 6CAF also increased 
the number of antigen-stimulated CD3–CD56+ cells 
expressing CD69 1 hr after caffeine ingestion compared 
with PLA (1:4,000, p < .05; Table 1) and 2CAF (1:8,000, 
p < .05; Table 1). Regardless of caffeine dose, caffeine 
ingestion did not affect the geometric mean fluorescence 
intensity (GMFI) of CD69 expression on unstimulated 
or antigen-stimulated CD3–CD56+ cells.
Preliminary Testing
Approximately 2 weeks before the main trials began, 
participants were required to perform a continuous 
incremental exercise test to volitional fatigue on an 
electromagnetically braked cycle ergometer (Lode 
Excalibur, Groningen, Netherlands) to determine their 
peak oxygen consumption (VO2peak). They started cycling 
at a work rate of 95 W, with 35-W increments every 3 
min, continuing until they reached volitional exhaustion. 
Expired-gas samples were collected into Douglas bags 
during the third minute of each work-rate increment and 
the last minute of the exercise test, with heart rates being 
measured continuously via short-range radio telemetry 
(Polar FS1, Polar Electro Oy, Kempele, Finland). A para-
magnetic O2 analyzer (Servomex 1420B, Crowborough, 
UK) and an infrared CO2 analyzer (Servomex 1415B) 
were used to measure the percentages of O2 and CO2 in 
the expired-gas samples. The analyzers, along with a dry 
gas meter (Harvard Apparatus, Edenbridge, UK), were 
used to determine minute ventilation, O2 consumption, 
and CO2 production. A work rate equivalent to 70% 
VO2peak for each participant was interpolated from the VO2 
(L/min)–work rate (W) relationship. Participants then 
came back into the laboratory on a separate occasion to 
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undertake a familiarization trial. The familiarization trial 
required them to cycle for 90 min at 70% VO2peak on an 
electromagnetically braked cycle ergometer. Heart rate 
was monitored continuously during the familiarization 
trial, and 1-min expired-gas samples were collected at 
20-min intervals throughout to ensure that participants 
were exercising at the correct intensity.
Experimental Trial Procedures
Each participant was given a list of caffeine-containing 
foods and beverages and instructed to abstain from these 
for 60 hr before each main trial. Participants were also 
instructed to avoid alcohol consumption and strenuous 
physical activity in the 24 hr preceding each experimental 
Table 1 Data From Pilot Study, M (SD)
0 hr 1 hr 2.5 hr 3.5 hr
Serum caffeine concentration (μmol/L)
 PLA
 2CAF
 6CAF
0 (0)
0 (0)
0 (0)
0 (0)
16 (8)#†
48 (11)*†
0 (0)
17 (3)#†
47 (11)*†
0 (0)
15 (3)#†
43 (9)*†
Lymphocytes (× 109 cells/L)
 PLA
 2CAF
 6CAF
1.90 (0.30)
1.80 (0.40)
1.80 (0.30)
1.70 (0.20)
1.60 (0.40)
2.00 (0.30)
1.70 (0.30)
1.70 (0.30)
1.80 (0.50)
1.70 (0.30)
1.80 (0.30)
1.60 (0.30)
CD3–CD56+ cells (× 109 cells/L)
 PLA
 2CAF
 6CAF
0.30 (0.12)
0.22 (0.09)
0.29 (0.11)
0.22 (0.07)
0.21 (0.07)
0.41 (0.17)**††
0.28 (0.11)
0.20 (0.10)
0.37 (0.07)**
0.30 (0.16)
0.30 (0.13)
0.30 (0.06)
CD3–CD56+ CD69+ cells (× 106 cells/L)
 unstimulated PLA
 unstimulated 2CAF
 unstimulated 6CAF
 1:4,000 PLA
 1:4,000 2CAF
 1:4,000 6CAF
 1:8,000 PLA
 1:8,000 2CAF
 1:8,000 6CAF
27.25 (27.37)
25.60 (25.90)
54.27 (53.51)
49.80 (30.34)
32.88 (18.81)
46.55 (14.02)
38.82 (24.63)
33.04 (29.53)
50.78 (60.98)
16.73 (13.46)
28.52 (31.77)
23.62 (45.35)
31.16 (18.84)
55.45 (47.82)
68.02 (28.54)‡
41.60 (34.46)
29.76 (22.69)
47.09 (29.34)§
24.00 (18.97)
28.70 (36.05)
55.22 (45.20)
47.72 (22.09)
49.21 (37.71)
80.83 (33.30)††
43.23 (21.72)
29.51 (29.38)
60.87 (43.34)††
35.39 (27.21)
30.18 (34.85)
33.81 (24.71)
61.52 (37.38)
96.12 (96.79)
61.75 (30.13)
57.02 (32.82)
62.34 (59.89)
54.94 (21.33)
CD3–CD56+ CD69+ GMFI
 unstimulated PLA
 unstimulated 2CAF
 unstimulated 6CAF
 1:4,000 PLA
 1:4,000 2CAF
 1:4,000 6CAF
 1:8,000 PLA
 1:8,000 2CAF
 1:8,000 6CAF
100 (0)
100 (0)
100 (0)
100 (0)
100 (0)
100 (0)
100 (0)
100 (0)
100 (0)
97 (11)
115 (30)
100 (11)
107 (14)
100 (16)
105 (9)
117 (36)
107 (12)
107 (13)
103 (17)
104 (22)
112 (30)
119 (17)
101 (18)
111 (20)
120 (28)
109 (16)
113 (17)
100 (17)
111 (28)
109 (23)
119 (28)
115 (21)
121 (34)
132 (55)
113 (12)
116 (29)
Note. PLA = 0 mg/kg body mass of caffeine; 2CAF = 2 mg/kg body mass of caffeine; 6CAF =6 mg/kg body mass of caffeine; GMFI = geometric 
mean fluorescence intensity. The GMFI values are expressed as a percentage relative to presupplement (0 hr) value.
*p < .01, **p < .05: significantly higher on 6CAF than PLA and 2CAF. #Significantly higher on 2CAF than PLA, p < .01. ‡Significantly higher on 
6CAF than PLA, p < .05. §Significantly higher on 6CAF than 2CAF, p < .05. †p < .01, ††p < .05: significantly higher than 0 hr within trial.
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trial. In an attempt to standardize nutritional status, par-
ticipants completed a 24-hr food diary the day before 
the first main trial and were asked to follow this during 
the 24 hr preceding the second and third main trials. 
They performed three main exercise trials, with 1 week 
between trials. Participants were randomly assigned to 
the PLA, 2CAF, or 6CAF trial and acted as their own 
controls in a repeated-measures, single-blind, crossover 
design. They arrived at the laboratory at 8:20 a.m. after 
an overnight fast of 12 hr. After 10 min of resting quietly 
an initial (presupplement) blood sample was obtained 
from an antecubital forearm vein by venipuncture. After 
the blood sample, participants ingested 0, 2, or 6 mg/kg 
body mass of caffeine powder (BDH Laboratory Supplies, 
Poole, UK) taken in the form of cellulose capsules (G & 
G Food Supplies Ltd., West Sussex, UK) with 300 ml 
plain water. For the 0 (PLA) trial, participants ingested 6 
mg/kg body mass of dextrose powder (BDH Laboratory 
Supplies). They then rested quietly in the laboratory for 
1 hr before a further (preexercise) venous blood sample 
was taken, after which preexercise body mass (in shorts 
only) was recorded. Immediately after this, participants 
began cycling on an electromagnetically braked cycle 
ergometer for 90 min at a work rate equivalent to 70% 
VO2peak (213 ± 22 W). During the 90-min cycle, their 
heart rate was recorded every 15 min. Participants also 
consumed 2 ml/kg body mass of plain water every 15 
min throughout the exercise in an attempt to standardize 
fluid intake. At 20, 50, and 80 min of exercise, 1-min 
expired-gas samples were collected to determine VO2 
and VCO2 to ensure that participants were exercising at 
the required intensity and to allow estimation of fat and 
carbohydrate oxidation, as well as energy expenditure 
using stoichiometric equations. A further venous blood 
sample (postexercise) was obtained immediately after 
cessation of 90 min of exercise, before postexercise 
body mass (in shorts only) was recorded. Participants then 
consumed 5 ml/kg body mass of plain water and rested 
quietly in the laboratory for another hour before a final 
venous blood sample (1 hr postexercise) was obtained. 
During this time no additional food or fluid was admin-
istered to participants. For all venous blood samples, 20 
ml of blood was obtained, with all samples taken from 
participants in an upright seated position. Laboratory 
conditions throughout the study were 19.6 ± 0.5 °C and 
35.7% ± 5.4% relative humidity.
Total Lymphocyte Count  
and Plasma Volume
Blood samples were collected into three evacuated 
monovette tubes (Starstedt, Leicester, UK), one contain-
ing K3EDTA (1.6 mg EDTA/ml blood), one containing 
lithium heparin (16 IU heparin/ml blood), and one con-
taining no additive to obtain serum, as well as a sterile 
5-ml bijou tube (Sterilin, Staffordshire, UK) containing 
15 μl heparin (15 IU heparin/ml blood). Blood collected 
into the K3EDTA monovette (7.5 ml) was analyzed for 
total and differential leukocyte counts and hematocrit 
and hemoglobin contents using a hematology analyzer 
(Ac•T 5diff analyzer, Beckman Coulter, UK). Plasma 
volume changes were estimated according to Dill and 
Costill (1974).
Lymphocyte Culture
Five milliliters of whole blood transferred into the sterile 
bijou tube containing heparin were immediately placed 
on ice and mixed (Thermo Denley, Spiramix) for 20 
min before setting up cultures as follows: Cells were 
cultured in Falcon 12 × 75-mm polystyrene tubes with 
caps (Becton Dickinson Biosciences, Oxford, UK), and 
for all samples stimulated and unstimulated cultures were 
set up. Tubes were stimulated by a 1:400 or 1:800 Pedia-
cel vaccine (Sanofi Pasteur MSD Ltd., Berkshire, UK) 
containing diphtheria toxoid, tetanus toxoid, acellular 
pertussis bacteria, poliovirus, and Haemophilus influenza 
Type B. Zero or 20 μl of Pediacel working vaccine (either 
1:400 or 1:800) was added to 200 µl of heparinized whole 
blood, giving a final stimulant concentration of 1:4,000 
(optimum) or 1:8,000 (suboptimum), before being incu-
bated for 20 hr at 37 °C, 5% CO2.
Assessment of Lymphocyte Subsets  
and CD69 Expression
After incubation, peripheral blood cells were labeled 
with a cocktail of Pharmingen monoclonal antibodies 
(Becton Dickinson Biosciences, Oxford, UK) against 
human lymphocyte cell-surface markers, as follows: 5 
μl CD3 FITC, 20 μl CD56 PECy5, and 10 μl CD69 PE. 
All samples were then vortexed and placed on ice for 20 
min, after which erythrocytes were lysed and leukocytes 
fixed using FACS Lyse (Becton Dickinson). Leukocytes 
were washed once in 3 ml ice-cold phosphate-buffered 
saline containing 0.1% bovine serum albumin and 2 mM 
EDTA before being resuspended in 400 μl of this solu-
tion. Three-color flow-cytometric analysis was performed 
using a FACS Calibur flow cytometer with Cell Quest 
analysis software (Becton Dickinson). Standard gating 
procedures using side-scatter versus forward-scatter 
plots were used to gate on the lymphocyte population. 
An unstained unstimulated sample was used to set 
quadrant boundaries to allow accurate acquisition of 
stained samples. All samples were set to collect 30,000 
lymphocyte events per analysis.
CD3+ (T-cell region) and CD56+ (NK-cell region) 
populations were acquired on quadrant dot plots of 
FL1 (CD3 FITC) and FL3 (CD56 PE-Cy5), along with 
quadrant dot plots of FL1 (CD3) and FL2 (CD69 PE) 
and quadrant dot plots of FL3 (CD56) and FL2 (CD69). 
These data were then displayed as histogram plots, the 
percentage of CD3– cells (total lymphocyte region minus 
the CD3+ region) expressing CD56+ was derived, and 
from this the percentage of total lymphocytes that were 
CD3–CD56+ was determined. CD3–CD56+ cells were then 
gated into a separate region, and a CD69+ histogram plot 
(Figure 1) of the cells in this region was used to calculate 
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the percentage expression and GMFI expression of 
CD69 of CD3–CD56+ cells. Cell counts of CD3–CD56+ 
were calculated by multiplying the percentage of these 
cells with the absolute lymphocyte count. The number 
of CD3–CD56+ cells expressing CD69 was determined 
by multiplying the percentage of cells expressing CD69 
by the total number of CD3–CD56+ cells. To facilitate 
intersubject comparisons, preexercise, postexercise, 
and 1 hr postexercise CD69 GMFI were expressed as a 
percentage of the presupplement value, as per Timmons, 
Tarnopolsky, Snider, and Bar-Or (2006).
Serum Caffeine and Plasma Cortisol 
Concentration
Serum was obtained from whole blood collected into a 
serum monovette (5.5 ml), which was left to clot for 1 hr 
before being centrifuged at 1,500 g for 10 min in a refrig-
erated centrifuge at 4 °C. Serum caffeine concentration 
was determined using a commercially available kit (Emit 
Caffeine Assay, Dade-Behring, Milton Keynes, UK) on 
an automatic photometric analyzer (COBAS Miras Plus, 
Roche Diagnostic Systems, Switzerland). Heparinized 
plasma was obtained from blood collected into a lithium 
heparin monovette (7.5 ml). Samples were spun at 1,500 
g for 10 min in a refrigerated centrifuge at 4 °C. Plasma 
cortisol concentration was determined by ELISA (DRG 
Diagnostics, DRG Instruments, Germany). The intra-
assay coefficients of variation for serum caffeine and 
plasma cortisol were 2.5% and 1.8%, respectively.
Statistical Analysis
Data in the text, tables, and figures are presented as 
M ± SD. The data were examined using a two-factor 
(Trial × Time) analysis of variance (ANOVA) with 
repeated-measures design. If the data were not normally 
distributed, statistical analysis was carried out on the 
logarithmic transformation of the data. Assumptions of 
sphericity in the data were checked, and adjustments in 
the degrees of freedom for the ANOVA were made using 
the Huynh–Feldt method of correction where appropriate. 
Any significant data were assessed using Student’s paired 
t tests with Holm–Bonferroni adjustments for multiple 
comparisons. Single comparisons between trials for 
overall exercise intensity, carbohydrate and fat oxida-
tion rates, rate of energy expenditure, and percentage 
contribution of substrate to energy expenditure were 
assessed using Student’s paired t tests. Statistical 
significance for this study was accepted at p < .05. The 
observed powers of the reported main and interaction 
effects are all >.8.
Results
Mean exercise intensity was similar between all trials 
(Table 2). Heart rates were comparable between trials 
during exercise (Table 2). Respiratory-exchange ratio 
and fat and carbohydrate oxidation rates did not differ 
between trials throughout exercise (Table 2). Likewise, 
energy expenditure and the percentage contribution of 
fat and carbohydrate were similar on all trials (Table 2).
After exercise, change in body mass (corrected for 
fluid intake) was similar for all trials (Table 2). There was 
no significant Time × Trial interaction effect for changes 
in plasma volume relative to the initial blood sample. 
However, after exercise plasma volume decreased on all 
trials (Table 2).
A significant Time × Trial interaction was found 
for serum caffeine concentration (p < .01), with higher 
concentrations pre-, post-, and 1 hr postexercise with 
6CAF than with PLA and 2CAF (p < .01; Figure 2). At 
these times, values with 2CAF were significantly higher 
than with PLA (p < .01; Figure 2). There were no signifi-
cant Time × Trial interaction effects for plasma cortisol 
Figure 1 — Histogram of CD69 expression on CD3–CD56+ NK cells.
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concentration for any of the trial comparisons. However, 
there was a main effect for trial (p < .01), with plasma 
cortisol concentrations with 6CAF significantly higher 
overall than with PLA (Table 3).
No significant Time × Trial interaction effect was 
found for total number of circulating lymphocytes, but 
there was a significant main effect for time (p < .01), 
with the circulating number of lymphocytes following 
Table 2 Physiological Variables, Respiratory-Exchange Ratio, 
Substrate Oxidation, and Energy Expenditure, M (SD)
PLA 2CAF 6CAF
Exercise intensity (% VO2peak)
Heart rate (beats/min)
Respiratory-exchange ratio
Fat oxidation rate (g/min)
Carbohydrate oxidation rate (g/min)
Energy expenditure (KJ/min)
% contribution fat 
% contribution carbohydrate
Body-mass change (kg)
Plasma volume change (%)
72.0 (3.2)
155 (9)
0.92 (0.05)
0.45 (0.29)
2.67 (0.61)
63 (3)
27 (17)
73 (17)
–1.5 (0.3)
–8.2 (5.2)
72.8 (3.3)
159 (8)
0.92 (0.06)
0.46 (0.30)
2.69 (0.57)
64 (4)
28 (18)
72 (18)
–1.6 (0.3)
–8.0 (5.0)
73.3 (3.3)
161 (8)
0.92 (0.06)
0.48 (0.29)
2.69 (0.59)
64 (4)
29 (18)
71 (18)
–1.6 (0.3)
–8.5 (5.4)
Note. PLA = 0 mg/kg body mass of caffeine; 2CAF = 2 mg/kg body mass of caffeine; 6CAF =6 
mg/kg body mass of caffeine. Values are mean of all recordings throughout exercise (SD).
Figure 2 — Serum caffeine concentrations during PLA (0 mg/kg body mass of caffeine), 2CAF (2 mg/kg body mass of caffeine), 
and 6CAF (6 mg/kg body mass of caffeine) trials, M ± SD. *Significantly higher on 6CAF than PLA and 2CAF (p < .01). **Sig-
nificantly higher on 2CAF than PLA (p < .01). †Significantly higher than presupplement within trial (p < .01). 
Intensive Exercise, NK Cells and Caffeine  161
a biphasic response to exercise (Table 3). A significant 
Time × Trial interaction was found for the number 
of CD3–CD56+ cells in the circulating lymphocyte 
population, with values higher with 6CAF postexercise 
than with PLA (p < .01; Table 3). 6CAF also showed 
a higher number of CD3–CD56+ cells in the circulating 
lymphocyte population than did 2CAF (main effect for 
trial; p < .05).
There were no significant Time × Trial interaction 
effects for the number of unstimulated or antigen-
stimulated CD3–CD56+ cells expressing CD69 for 
any of the trial comparisons. However, the number of 
unstimulated and antigen-stimulated CD3–CD56+ cells 
expressing CD69 increased above presupplement values 
at postexercise and decreased below baseline 1 hr postex-
ercise (main effect for time: p < .01; Table 3).
There was a significant interaction effect for the 
GMFI of CD69 expression on unstimulated CD3–CD56+ 
cells, with both 2CAF and 6CAF demonstrating a signifi-
cant increase 1 hr postexercise compared with PLA (both 
p < .05; Figure 3[a]). Values with 2CAF also appeared 
to be higher than with PLA preexercise; this approached 
significance (p = .061). GMFI of CD69 expression on 
unstimulated CD3–CD56+ cells was also higher overall 
with 2CAF than 6CAF (main effect for trial, p < .05; 
Figure 3[a]). When cells were stimulated, GMFI of CD69 
expression on antigen-stimulated (1:4,000) CD3–CD56+ 
cells tended to be higher with 6CAF than PLA (p for 
Table 3 Plasma Cortisol Concentration, Total Lymphocyte Count, Number of Circulating CD3–
CD56+ Cells and Number of Circulating CD3–CD56+ Cells Expressing CD69, M (SD)
Presupplement Preexercise Postexercise 1 hr postexercise
Plasma cortisol concentration (nmol/L)a,b
 PLA
 2CAF
 6CAF
479 (68)
477 (69)
491 (67)
375 (91)
350 (102)
389 (55)
443 (155)
502 (191)
518 (148)
380 (131)
409 (156)
468 (114)
Lymphocytes (× 109 cells/L)c
 PLA
 2CAF
 6CAF
2.10 (0.60)
2.10 (0.50)
2.10 (0.60)
1.70 (0.40)
1.80 (0.40)
1.90 (0.40)
2.30 (0.80)
2.50 (0.70)
2.70 (1.10)
1.50 (0.40)
1.50 (0.40)
1.50 (0.40)
CD3–CD56+ CD69+ cells (× 109 cells/L)d,e
 PLA
 2CAF
 6CAF
0.39 (0.17)
0.42 (0.16)
0.42 (0.24)
0.33 (0.16)
0.39 (0.15)
0.43 (0.19)
0.62 (0.30)††
0.68 (0.30)
0.79 (0.36)*†
0.28 (0.12)††
0.25 (0.11)
0.31 (0.14)
Unstimulated CD3–CD56+ CD69+ cells (× 106 cells/L)d,e
 PLA
 2CAF
 6CAF
39.77 (33.09)
34.24 (22.83)
34.42 (19.69)
30.21 (23.03)
31.31 (17.98)
39.51 (23.92)
49.08 (34.96)
55.50 (45.06)
65.09 (32.28)
20.64 (13.54)
19.25 (15.25)
23.86 (14.80)
1:4,000 CD3–CD56+ CD69+ cells (× 106 cells/L)d
 PLA
 2CAF
 6CAF
47.74 (21.97)
49.53 (24.04)
53.57 (25.63)
41.95 (22.16)
65.76 (39.63)
75.78 (70.33)
82.38 (40.11)
95.35 (63.38)
97.94 (30.69)
42.14 (24.25)
39.30 (26.05)
41.76 (24.66)
1:8,000 CD3–CD56+ CD69+ cells (× 106 cells/L)d
 PLA
 2CAF
 6CAF
37.88 (17.30)
40.65 (20.54)
40.31 (27.43)
41.46 (23.29)
55.58 (31.05)
61.80 (63.82)
69.51 (37.43)
75.19 (50.90)
78.97 (45.52)
26.16 (15.38)
28.24 (25.63)
32.67 (21.90)
Note. PLA = 0 mg/kg body mass of caffeine; 2CAF = 2 mg/kg body mass of caffeine; 6CAF =6 mg/kg body mass of caffeine. 
aMain effect for time: significantly lower than presupplement at preexercise, p < .01. bMain effect for trial: significantly higher on 6CAF than PLA, 
p < .01. cMain effect for time: significantly different from presupplement at preexercise, postexercise, and 1 hr postexercise, p < .01. dMain effect 
for time: significantly different from presupplement at postexercise and 1 hr postexercise, p < .01. eMain effect for trial: significantly higher on 
6CAF than PLA and 2CAF, p < .05.
*p < .05: significantly higher on 6CAF than PLA. †p < .01, ††p < .05: significantly different than presupplement within trial.
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Figure 3(a) — Geometric mean fluorescence intensity of CD69 expression on unstimulated CD3–CD56+ natural killer cells within 
the circulating lymphocyte population during PLA (0 mg/kg body mass of caffeine), 2CAF (2 mg/kg body mass of caffeine), and 
6CAF (6 mg/kg body mass of caffeine) trials, M ± SD. *Significantly higher than PLA (p < .05). †Significantly higher than pre-
supplement within trial (p < .05). Values are expressed as a percentage of presupplement value.
Figure 3(b) — Geometric mean fluorescence intensity of CD69 expression on 1:4,000 antigen-stimulated CD3–CD56+ natural 
killer cells within the circulating lymphocyte population during PLA (0 mg/kg body mass of caffeine), 2CAF (2 mg/kg body mass of 
caffeine), and 6CAF (6 mg/kg body mass of caffeine) trials, M ± SD. Values are expressed as a percentage of presupplement value.
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interaction = .09; Figure 3[b]), and the GMFI of CD69 
expression on antigen-stimulated (1:8,000) CD3–CD56+ 
cells was significantly higher with 2CAF 1 hr postexer-
cise than with PLA (p < .05; Figure 3[c]). There were no 
differences between 2CAF and 6CAF with either dose of 
antigen (Figures 3[b] and 3[c], respectively).
Discussion
The findings of the current study suggest that, compared 
with placebo, ingesting 2 or 6 mg/kg body mass of caf-
feine 1 hr before exercise is associated with increases in 
the natural state of activation of circulating NK cells and 
increases in the GMFI of CD69 expression on antigen-
stimulated NK cells 1 hr after high-intensity prolonged 
cycling. The effects of caffeine on NK-cell activation 
1 hr after prolonged intensive cycling were not found 
to be dose dependent. In addition, only a large dose of 
caffeine (6 mg/kg) increased the trafficking of NK cells 
into the peripheral circulation immediately postexercise 
compared with placebo.
In the current study both a high and low dose of 
caffeine increased unstimulated and antigen-stimulated 
NK-cell activation 1 hr after 90 min of cycling at 70% 
VO2peak. The apparently positive effects of caffeine on 
NK-cell activation may be explained by its ability to 
alter intracellular cAMP. The actions of adenosine 
via A2A adenosine receptors (Priebe et al., 1990) have 
been shown to inhibit NK-cell function via activation 
of adenylate cyclase and increased intracellular cAMP 
concentration (Goto, Herberman, Maluish, & Strong, 
1983), and the actions of adenosine via A1 adenosine 
receptors have been shown to enhance NK-cell function 
via suppression in cAMP (Goto et al., 1983). It is known 
that caffeine is a nonselective adenosine-receptor antago-
nist. Therefore, it is suggested that both the high and low 
dose of caffeine acted to impede the adenosine-mediated 
increase in intracellular cAMP concentration in NK cells 
via antagonism of A2A adenosine receptors (Raskovalova 
et al., 2006). Although plasma adenosine concentration 
was not measured in this study, it has been reported in 
rats that doses of caffeine corresponding to those used in 
this study increased plasma concentrations of adenosine 
via adenosine-receptor blockade in a dose-dependent 
manner (Conlay, Conant, deBros, & Wurtman, 1997).
Caffeine also has the potential to reduce NK-cell 
function indirectly via its ability to increase the release 
of epinephrine (Graham, 2001). Epinephrine stimulates 
β2 adrenoreceptors on NK cells and in turn increases the 
level of intracellular cAMP, leading to an inhibition of 
NK-cell function (Murray et al., 1992). Because both caf-
feine doses in this study increased, rather than decreased, 
NK-cell activation 1 hr after exercise it is unlikely that 
epinephrine played a principal role in NK-cell activation 
Figure 3(c) — Geometric mean fluorescence intensity of CD69 expression on 1:8,000 antigen-stimulated CD3–CD56+ natural 
killer cells within the circulating lymphocyte population during PLA (0 mg/kg body mass of caffeine), 2CAF (2 mg/kg body mass 
of caffeine), and 6CAF (6 mg/kg body mass of caffeine) trials, M ± SD. *Significantly higher than PLA (p < .05). †Significantly 
higher than presupplement within trial (p < .05). Values are expressed as a percentage of presupplement value.
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here. However, it should be noted that any effect of caf-
feine on antigen-stimulated NK-cell activation is most 
likely the net result of a number of stimulatory and inhibi-
tory influences. Therefore, in the current study it could 
be argued that A2A adenosine-receptor antagonism may 
have exerted a stronger influence on NK-cell function 
than enhanced adrenergic stimulation.
In the current study a high dose of caffeine increased 
the trafficking of NK cells into the circulation immedi-
ately after exercise cessation compared with placebo. 
Epinephrine is known to modulate the expression of 
adhesion molecules on NK cells, leading to increased 
mobilization of these cells into the circulation after high-
intensity exercise (Benschop, Rodriguez-Feuerhahn, & 
Schedlowski, 1996; Nagao, Suzui, Takeda, Yagita, & 
Okumura, 2000). With this in mind, an alternative action 
of caffeine in this study might have been to influence an 
epinephrine-mediated mobilization into the peripheral 
circulation of a specific population of NK cells with an 
activated phenotype or with increased propensity for 
activation when stimulated. Although plasma epineph-
rine concentration was not measured in this study, our 
participants, exercise protocol, and serum caffeine con-
centration after exercise on the 6 mg/kg caffeine dose are 
comparable to those of Walker et al. (2006), who found a 
significantly higher plasma adrenaline concentration after 
exercise with 6 mg/kg caffeine than with placebo (current 
study 44 μM, Walker et al. 46 μM). Although high doses 
of caffeine (6 and 9 mg/kg) appear to increase plasma 
concentrations of epinephrine, it has been reported that a 
low caffeine dose (3 mg/kg) has little effect in increasing 
plasma epinephrine concentration in response to high-
intensity exercise (Graham & Spriet, 1995). This may 
help explain why in the current study NK-cell recruit-
ment into the circulation after exercise was higher with 
6CAF, with no differences between 2CAF and PLA at 
this time, and why there was a higher overall number of 
naturally activated NK cells in the peripheral circulation 
with 6CAF than with PLA and 2CAF.
However, we should bear in mind that this study used 
whole-blood cultures when stimulating cells. Although 
whole-blood cultures are the closest one can get to in vivo 
conditions in terms of retaining the proximity between leu-
kocytes and extracellular milieu (Gleeson, 2007), they make 
it difficult to ascertain whether the vaccine used in this study 
directly affected NK-cell activation or exerted its effects 
on other bystander cells in the culture (i.e., monocytes 
or T cells) that subsequently influenced NK-cell activa-
tion. Stimulating NK-cell cultures depleted of T cells 
and monocytes could help ascertain whether the Pediacel 
vaccine used in this study directly activated NK cells.
This study is the first to report apparently positive 
effects of a low dose of caffeine on antigen-stimulated 
NK-cell activation 1 hr after high-intensity exercise. Fur-
thermore, the study has demonstrated that a low dose of 
caffeine appears to exert effects on NK-cell activation 1 
hr after prolonged intensive cycling similar to those of a 
dose 3 times as large. This is a significant finding because 
many athletes only ingest small amounts of caffeine to 
enhance athletic performance (Chester & Wojek, 2008), 
and it suggests that a low dose of caffeine, as well as being 
ergogenic (Cox et al., 2002), may have the potential to 
strengthen an athlete’s first line of defense against infec-
tious agents after high-intensity exercise. However, it is 
difficult to extrapolate an enhancement in NK-cell activa-
tion to an enhancement of an athlete’s overall immunity 
1 hr after high-intensity exercise; the enhancement in 
this study relates to one particular cellular response and 
as such may not accurately represent what is happening 
to the rest of the athlete’s immune system. Future use of 
in vivo cell-mediated immune-function tests would help 
shed light on any effect of caffeine ingestion on whole-
body cell-mediated immunity.
Although in this study the effects of ingesting 6 mg/
kg body mass of caffeine on antigen-stimulated NK-
cell activation did not reach statistical significance, it 
showed a trend for increased cellular responses that was 
comparable to that observed with ingestion of 2 mg/kg 
body mass. Pilot work from our group has previously 
demonstrated that 6 mg/kg body mass of caffeine was 
effective at increasing antigen-stimulated NK-cell activa-
tion after an identical exercise protocol (Fletcher et al., 
2008). The current participants are comparable to those 
used for our pilot work, and diet, exercise, and caffeine 
controls before the trial were identical to the former study. 
However, interindividual variations in responses were 
greater here than in our pilot work. This may relate to 
individual differences in habitual caffeine intake, because 
caffeine consumption here was more varied among the 
participants than in our previous work. Indeed, large 
interindividual differences in athletes’ physiological 
and performance responses to the effects of caffeine 
have been reported (Desbrow, Barrett, Minahan, Grant, 
& Leveritt, 2009; Skinner, Jenkins, Coombes, Taaffe, & 
Leveritt, 2010). Future investigations into the effects of 
caffeine on specific groups of caffeine users—that is, 
light, moderate, or high users—would help clarify reasons 
for such variability.
In conclusion, the findings of the current study sug-
gest that both a high and low dose of caffeine are associ-
ated with an increase in the natural state of activation of 
NK cells, in addition to having positive effects on antigen-
stimulated NK-cell activation 1 hr after high-intensity 
prolonged cycling. However, there was no obvious effect 
of caffeine dose on these responses. It is suggested that 
these findings reflect an overriding A2A antagonistic effect 
of caffeine or a caffeine-influenced epinephrine-mediated 
mobilization of a specific population of activated NK 
cells. Most likely it is a combination of the two. Despite 
both doses of caffeine having a positive influence on 
NK-cell activation 1 hr after high-intensity exercise, the 
clinical significance of these findings in terms of subse-
quent infection risk is as yet unclear.
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